Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019

Study Overview
=================
Brief Summary
-----------------
This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative hospital stay.

Detailed Description
-----------------
This study will be conducted at the Lung Center of the Philippines. The study design is a retrospective case series implemented via chart review. Online and written patient records will be reviewed to determine the baseline patient characteristics and the preoperative outcomes. Patients who recovered from COVID-19 will be selected from those who underwent anatomic lung resection from June 1, 2020 to May 31, 2022. This study will be done in accordance with the Helsinky Declaration and Good Clinical Practice Guidelines, and will be subject for approval of the institutional Ethics and Technical Review Boards. Descriptive statistics will be used to describe patient characteristics and perioperative outcomes.

Official Title
-----------------
Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019 (COVID-19): a Two-Year Retrospective Case Series

Conditions
-----------------
COVID-19, Lung Cancer, Lung TB, Hemoptysis

Intervention / Treatment
-----------------
* Procedure: anatomic lung resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: underwent anatomic lung resection previous COVID-19 infection documented by nasopharyngeal swab RT-PCR or GeneXpert with negative nasopharyngeal swab RT-PCR or GeneXpert prior to lung resection Exclusion Criteria: with incomplete patient records
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients who recovered from COVID-19<br>patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy) | Procedure: anatomic lung resection<br>* includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate | proportion of patients who died due to perioperative complications | perioperative period (up to 30 days after anatomic lung resection) | 
| Major complication rate | proportion of patients who develop acute kidney injury, acute myocardial infarction, acute respiratory distress syndrome (ARDS), acute respiratory failure, atelectasis requiring intervention, bronchopleural fistula, empyema thoracis, hemothorax, pneumonia, stroke or venous thromboembolism | perioperative period (up to 30 days after anatomic lung resection) | 
| Minor complication rate | proportion of patients who develop atrial fibrillation, pneumothorax or prolonged air leak | perioperative period (within 30 days after anatomic lung resection) | 
| Length of postoperative hospital stay | time duration from surgery to discharge order | perioperative period (up to 30 days after anatomic lung resection) |